

**60<sup>th</sup> ONCOLOGY CONGRESS**  
**November 29<sup>th</sup> – December 2<sup>nd</sup> 2023**  
**“Sava Centar”, Belgrade, Serbia**

**SCIENTIFIC PROGRAM**  
**HALL A**

**DAY 1, November 29<sup>th</sup> 2023, WEDNESDAY**

<b>09:00-10:00</b>	<b>CONGRESS OPENING CEREMONY</b>	
	<p><b>Nada Santrac</b>, Serbian Medical Society Oncology Section, Secretary – Welcome message &amp; Congress overview  <b>Nebojsa Stankovic</b>, Academy of Medical Sciences, Serbian Medical Society, Vice-president  <b>Ferenc Vicko</b>, Ministry of Health, State Secretary  <b>Milan Zegarac</b>, Institute for Oncology and Radiology of Serbia, General Manager  <b>Milena Cavic</b>, Serbian Association for Cancer Research, President  <b>Dragan Kodzo</b>, UMSTBS, President  <b>Savo Pilipovic</b>, Serbian Association of Patients, President  <b>Ivan Markovic</b>, Serbian Medical Society Oncology Section, President – Oncology Section historical overview &amp; Congress opening</p>	
<b>10:00-11:00</b>	<p><b>Scientific session 1</b>  <b>Lung Cancer Treatment – part 1</b>  <b>Early and locally advanced non-small cell lung cancer (NSCLC)</b>  <u>Moderators:</u> Davorin Radosavljevic, Natasa Jovanovic Korda, Dejan Stojiljkovic  <u>Panelists:</u> Tatjana Arsenijevic, Bojan Zaric, Milica Kontic, Milan Rancic, Milan Savic</p>	
10:00-10:12	Perioperative therapy of NSCLC	Jelena Spasic
10:12-10:22	Case report 1: Stage II + discussion	Mladjana Savic
10:22-10:32	Case report 2: Stage IIIA + discussion	Filip Markovic
10:32-10:42	Case report 3: Stage IIIB + discussion	Vladan Mutavdzic
10:42-10:54	Tracheal resections - when and how?	Servet Bolukbas
10:54-11:00	Conclusions	
<b>11:00-12:00</b>	<p><b>Sponsored symposium 1</b>  <b>SPECIAL GOLDEN SPONSORSHIP</b>  <b>AstraZeneca</b>  <b>EGFRevolution</b>  Panel: Bojan Zaric (moderator), Milica Kontic, Milan Savic, Milena Cavic</p>	
12:00-13:00	LUNCH	
<b>13:00-13:45</b>	<b>Sponsored symposium 2</b>	

	<i>GOLDEN SPONSORSHIP</i> <b>Pfizer</b> <b>Optimal first-line treatment for metastatic ALK+ NSCLC</b> Davorin Radosavljevic: Unmet medical need in ALK+ NSCLC Bojan Zaric: Why to choose lorlatinib in 1L? Vesna Ceriman: Managing adverse events in ALK+ NSCLC	
<b>13:45-14:30</b>	<b>Scientific session 2</b> <b>Lung Cancer Treatment – part 2</b> <b>Small cell lung cancer (SCLC)</b> <u>Moderators:</u> Davorin Radosavljevic, Natasa Jovanovic Korda, Dejan Stojiljkovic <u>Panelists:</u> Zoran Andric, Tatjana Boskovic, Nebojsa Maric, Jelena Spasic, Marta Velinovic, Marina Cekic	
13:45-13:57	Immunotherapy in treatment of SCLC	Daliborka Bursac
13:57-14:07	Case report 1: First line of treatment in stages I-III + discussion	Kristina Jovic
14:07-14:17	Case report 2: First line of treatment in stage IV + discussion	Dimitrije Kolovic
14:17-14:27	Case report 3: Refractory SCLC + discussion	Nadezda Milutinovic
14:27-14:30	Conclusions	
<b>14:30-15:30</b>	<b>Sponsored symposium 3</b> <i>PLATINUM SPONSORSHIP</i> <b>ROCHE</b> <b>From Riddle to Clarity: Navigating Lung Cancer Labyrinth</b>	
<b>15:30-16:30</b>	<b>Sponsored symposium 4</b> <i>PLATINUM SPONSORSHIP</i> <b>ROCHE</b> <b>Breast Cancer - The Labyrinth</b>	
<b>16:30-17:00</b>	<b>Scientific session 3</b> <b>Medical oncology in breast cancer – part 1</b> <u>Moderator:</u> Snezana Susnjar	
16:30-16:45	Check point inhibitors in patients with early triple negative breast cancer: it is a prime time	Peter Schmid (pre-recorded)
16:45-17:00	Panel discussion: Joseph Gligorov, Semir Beslija, Sanja Lekic	
17:00-17:10	Coffee break	
<b>17:10-17:40</b>	<b>Sponsored symposium 5</b> <i>SPECIAL GOLDEN SPONSORSHIP</i> <b>AstraZeneca</b> <b>Unfolding HER2 spectrum together</b> Panel: Lazar Popovic, Ljiljana Stamatovic, Ivana Bozovic Spasojevic	
<b>17:40-18:10</b>	<b>Scientific session 4</b> <b>Medical oncology in breast cancer – part 2</b> <u>Moderator:</u> Ivana Bozovic Spasojevic	
17:40-17:55	Systemic treatment for HR-pos / HER2-neg metastatic breast cancer: CDK4/6 inhibitors and beyond	Dejan Juric

17:55-18:10	Panel discussion: Joseph Gligorov, Simona Borstnar, Ana Cvetanovic, Dejan Juric	
<b>18:10-18:40</b>	<b>Scientific session 5</b> <b>Medical oncology in breast cancer – part 3</b> <u>Moderator: Ljiljana Stamatovic</u>	
18:10-18:25	New standards in HER2-positive metastatic breast cancer	Giuseppe Curigliano (online)
18:25-18:40	Panel discussion: Joseph Gligorov, Natalija Dedic Plavetic, Lazar Popovic, Giuseppe Curigliano	
<b>18:40-19:10</b>	<b>Scientific session 6</b> <b>Medical oncology in breast cancer – part 4</b> <u>Moderator: Zorica Tomasevic</u>	
18:40-18:55	QoL and supportive care in breast cancer survivors	Antonio Di Meglio
18:55-19:10	Panel discussion: Joseph Gligorov, Zdenka Gojkovic, Antonio Di Meglio	
19:10-20:10	ORAL PRESENTATIONS Moderator: Ana Cvetanovic, Marko Spasic	
<b>DAY 2, November 30<sup>th</sup> 2023, THURSDAY</b>		
<b>08:00-08:30</b>	<b>Sponsored symposium 1</b> <b>Farmix</b> <b>New possibilities in reconstructive breast surgery – advantages of biological matrix</b> Jovana Koncar: Meshes - place and role in reconstructive breast surgery Nazaret Ruiz Lopez: Biological meshes in breast reconstruction. Experience with EXAFLEX (5 years follow-up) Olivera Kosovac: Experience with biological meshes in breast reconstruction – Exaflex case report	
<b>08:30-09:20</b>	<b>Scientific session 1</b> <b>Early Breast Cancer – part 1: Imaging</b> <u>Moderator: Mirjan Nadrljanski</u>	
08:30-08:45	Radiological diagnostic – beyond conventional	Marijana Basta Nikolic
08:45-09:00	Biopsy procedures – beyond conventional	Mirjan Nadrljanski
09:00-09:20	Q&A & conclusions	
09:20-09:30	Coffee break	
<b>09:30-10:30</b>	<b>Scientific session 2</b> <b>Early Breast Cancer – part 2: Oncoplastic surgery</b> <u>Moderator: Ivan Markovic</u>	
09:30-09:55	Oncoplastic surgery for early BC: who, when and how?	Yazan Masannat
09:55-10:25	Panel discussion: Yazan Masannat, Vicko Ferenc, Marko Buta, Jovana Koncar, Branka Radmanovic, Olivera Kosovac, Marko Spasic, Aleksandar Karanikolic	
10:25-10:30	Conclusions	
<b>10:30-11:00</b>	<b>Sponsored symposium 2</b> <i>SPECIAL GOLDEN SPONSORSHIP</i> <b>AstraZeneca</b>	

	<b>Decoding gBRCAm in early BReast Cancer: Why, When, Whom and How should we test?</b> Panel: Lazar Popovic, Ivan Markovic, Marijana Milovic - Kovacevic, Ana Krivokuca	
11:00-11:20	Coffee break	
<b>11:20-12:10</b>	<b>Scientific session 3</b> <b>Early Breast Cancer – part 3: Radiotherapy</b> <u>Moderator:</u> Jasmina Mladenovic	
11:20-11:35	Partial breast irradiation	Olivera Ivanov
11:35-11:50	Omission of breast radiotherapy in elderly patients	Jasmina Mladenovic
11:50-12:05	Panel discussion: Olivera Ivanov, Aleksandar Rankovic, Ivana Rosic, Milica Radic	
12:05-12:10	Conclusions	
<b>12:10-12:55</b>	<b>Sponsored symposium 3</b> <i>GOLDEN SPONSORSHIP</i> <b>Pfizer</b> <b>IBRANCE® writes stories</b> Lazar Popovic (Serbia), Simona Borstnar (Slovenia), Natalija Dedic Plavetic (Croatia)	
12:55-13:00	Break	
<b>13:00-14:00</b>	<b>Sponsored symposium 4</b> <i>GOLDEN SPONSORSHIP</i> <b>Novartis</b> <b>Natalee in the era of Monaleesa: New perspectives in treatment of HR+ breast cancer</b> Moderator: Ljiljana Stamatovic Panelists: Ana Cvetanovic, Ivana Kolarov Bjelobrk, Ivana Minic	
14:00-15:00	LUNCH	
<b>15:00-15:45</b>	<b>Sponsored symposium 5</b> <i>GOLDEN SPONSORSHIP</i> <b>MSD</b> <b>Time as a key: the importance of timely treatment and equal access</b> Moderator: Lazar Popovic Panelists: Suzana Matkovic, Ljiljana Stamatovic, Zafir Murtezani	
<b>16:00-16:45</b>	<b>Scientific session 4</b> <b>Gynecological malignancies – part 1: Cervical cancer</b> <u>Moderator:</u> Aleksandar Stefanovic	
16:00-16:15	Current recommendations for treatment of cervical cancer	Aleksandar Tomasevic
16:15-16:45	Panel discussion: Aljosa Mandic, Petar Radlovic, Aleksandar Tomasevic, Olivera Ivanov, Ilinka Todorovska	
16:45-17:30	<b>Scientific session 5</b> <b>Gynecological malignancies – part 2: Endometrial cancer</b> <u>Moderator:</u> Aljosa Mandic	

16:45-17:00	Current recommendations for treatment of endometrial cancer	Lazar Nejkovic
17:00-17:30	Panel discussion: Svetlana Milenkovic, Lazar Nejkovic, Bojana Gutic, Mirjana Mikovic, Vladan Popovic	
17:30-17:40	Coffee break	
<b>17:40-18:25</b>	<b>Scientific session 6</b> <b>Gynecological malignancies – part 3: Ovarian cancer</b> <u>Moderator: Ljiljana Stamatovic</u>	
17:40-17:55	Current recommendations for treatment of ovarian cancer	Vladimir Pazin
17:55-18:25	Panel discussion: Vladimir Pazin, Marijana Milovic Kovacevic, Sasa Kadija, Jasmina Nedovic	
18:25-18:30	Key messages for cervical cancer treatment	Aleksandar Stefanovic
18:30-18:35	Key messages for endometrial cancer treatment	Aljosa Mandic
18:35-18:40	Key messages for ovarian cancer treatment	Ljiljana Stamatovic
18:40-19:00	ORAL PRESENTATIONS Moderator: Marijana Milovic Kovacevic, Petar Radlovic	
<b>DAY 3, December 1<sup>st</sup> 2023, FRIDAY</b>		
<b>08:00-09:00</b>	<b>Scientific symposium 1</b> <b>Medical challenges in the digitalization era</b> <u>Moderators: Jelena Bojovic, Ivan Markovic</u>	
08:00-08:15	How future of bioresearch helps personalized oncology - Real World Evidence	Jelena Begovic
08:15-08:30	Is artificial intelligence our near future?	Branka Rakic
08:30-08:45	How bioanalysis helps treatment personalization - Real World Evidence	Natasa Milic
08:45-09:00	Q&A, discussion, conclusions	
<b>09:00-10:00</b>	<b>Scientific symposium 2</b> <b>Scientific network in oncology</b> <u>Moderators: Ivana Bozovic Spasojevic, Radmila Jankovic</u>	
09:00-09:15	Virusology in oncology, ROLERS PROJECT	Ana Banko
09:15-09:30	Adverse effects of medicines on the nervous system: predictability in preclinical development, HORIZONT PROJECT	Miroslav Savic
09:30-09:45	Profiling new biomarkers in rectal cancer using omics approaches - interim report of the STEPUPIORS Horizon Europe Project	Milena Cavic
09:45-10:00	Q&A, discussion, conclusions	
10:00-10:20	Coffee break	
<b>10:20-11:05</b>	<b>Sponsored symposium 1</b> <i>GOLDEN SPONSORSHIP</i> <b>MSD</b> <b>Keytruda's pioneering role in lung cancer survival</b>	

	Moderator: Bojan Zaric Panelists: Katja Mohorcic, Milica Kontic Jovanovic	
11:05-11:10	Break	
<b>11:10-11:30</b>	<b>Plenary lecture</b> <b>Early integrated rehabilitation of breast cancer patients in Slovenia</b> <b>Nikola Besic, Slovenia</b>	
11:30-11:40	Q&A	
11:40-12:00	Coffee break	
<b>12:00-13:00</b>	<b>Future of Oncology – access panel</b> <u>Moderator:</u> Ivan Markovic <u>Panelists:</u> Ministry of Health – Danica Grujicic, Republic Health Care Fund – Sanja Radojevic-Skodric, Institute for Oncology and Radiology of Serbia – Milan Zegarac, Davorin Radosavljevic, Institute for Oncology Vojvodina – Ferenc Vicko, INOVIA – Bojan Trkulja, Patients’ representative – Savo Pilipovic	
<b>13:00-14:05</b>	<b>Sponsored symposium 2</b> <b>Bristol Myers Squibb</b> <b>Immunotherapy: Standard of care for solid tumors</b> Suzana Matkovic: Melanoma – The longest mOS in melanoma treatment Zoran Andric: NSCLC – Nivo + Ipi consistent and significant long term OS benefit Svetlana Salma: RCC - Dual IO is SOC for metastatic RCC Marija Ristic: Gastric cancer – IO based therapy as a recommended frontline Discussion, Summary & Closure	
14:00-15:00	LUNCH	
<b>15:00-16:00</b>	<b>Scientific symposium 3</b> <b>Oncofertility: fertility preservation and pregnancy in breast cancer patients</b> <u>Moderators:</u> Vesna Kesic, Katarina Stefanovic	
15:00-15:15	Oncofertility: a bridge between reproduction and oncology	Vesna Kesic
15:15-15:25	Oncofertility: our experiences	Katarina Stefanovic
15:25-15:35	Ovarian stimulation in cancer patients	Snezana Vidakovic
15:35-15:45	ESMO Guidelines for fertility preservation and pregnancy in breast cancer patients	Snezana Susnjar
15:45-16:00	Panel discussion, panelists: Snezana Vidakovic, Snezana Susnjar	
<b>16:00-17:00</b>	<b>Scientific symposium 4</b> <b>Cardio-oncology</b> <u>Moderators:</u> Snezana Susnjar, Sonja Salinger	
16:00-16:15	Cardiotoxicity of cancer therapy: new guidelines	Thomas Suter
16:15-16:25	Current recommendations for evaluation of cardiotoxicity – how to improve collaboration between cardiologists and oncologists	Sonja Salinger
16:25-16:35	ESMO Guidelines for cardiotoxicity and case reports	Ivana Bozovic Spasojevic

16:35-16:45	Novel techniques for reducing cardiotoxicity after breast cancer postoperative radiotherapy	Sandra Radenkovic
16:45-17:00	Q&A, discussion	
17:00-17:10	Break	
<b>17:10-19:00</b>	<b>Scientific symposium 5</b> <b>Radiobiology – from basic research to clinical implementation</b> <u>Moderators: Tatjana Stanojkovic, Marina Nikitovic</u>	
17:10-17:25	Approaches to predicting radiation-induced fibrosis and mechanistic aspects learned from irradiation of fibroblasts in vitro	Carsten Herskind
17:25-17:40	Radiotheragnostics: predicting radiotherapy side effects to optimize treatment	Christopher Talbot
17:40-17:50	Genetic regulation of ferroptosis, a regulated cell death and promising target for treatment of cancer	Maja Živkovic, Aleksandra Stankovic
17:50-18:00	miRNAs – promising applications in radiotherapy	Danijela Stanisavljevic Ninkovic
18:00-18:10	Application of radiosensitizers and radioprotectors to increase the efficiency of radiotherapy	Ivana Matic, Ivana Pasic
18:10-18:20	The role of miRNA in lung cancer radiotherapy	Tatjana Arsenijevic
18:20-18:30	The importance of exosomes in regulating solid tumor radiosensitivity	Marija Popovic Vukovic
18:30-19:00	Q&A, discussion, conclusions	
19:00-20:00	<b>ORAL PRESENTATIONS</b> Moderator: Nada Santrac, Tamara Ursulovic	
<b>DAY 4, December 2<sup>nd</sup> 2023, SATURDAY</b>		
08:00-09:00	<b>ORAL PRESENTATIONS</b> Moderator: Milan Kocic, Neda Nikolic	
<b>09:00-10:00</b>	<b>Scientific symposium 1</b> <b>Soft tissue sarcomas – current protocols &amp; beyond</b> <u>Moderators: Srdjan Nikolic, Marco Fiore</u>	
	Introduction	
09:00-09:15	Modern standard approach to extremity and truncal soft tissue sarcoma	Marco Fiore
09:15-09:30	Panel discussion: Marco Fiore, Srdjan Nikolic, Jelena Sopta, Dusan Ristic	
09:30-09:45	The road to renewed surgical treatment for retroperitoneal sarcoma	Marco Fiore
09:45-10:00	Panel discussion: Marco Fiore, Srdjan Nikolic, Jelena Sopta, Dusan Ristic	
10:00-10:10	Coffee break	
<b>10:10-10:40</b>	<b>Sponsored symposium 1</b> <b>Amicus</b> <b>Vectibix – treatment choice in PRECISION therapy of mCRC</b> Moderator: Davorin Radosavljevic	

	Zafir Murtezani: ASCO 2022 – Paradigm Clinical Trial Nenad Mijalkovic: ASCO 2023 – Paradigm Clinical Trial Discussion	
<b>10:40-12:00</b>	<b>Scientific symposium 2</b> <b>Multidisciplinary treatment of digestive tract malignancies – part 1:</b> <b>Gastric and gastroesophageal cancer</b> <u>Moderators:</u> Srdjan Nikolic, Davorin Radosavljevic, Suzana Stojanovic Rundic <u>Panelists:</u> Milos Bjelovic, Ivan Nikolic, Nikola Milosevic, Neda Nikolic, Andreas Brandl	
10:40-10:55	Perioperative systemic therapy	Neda Nikolic
10:55-11:10	Surgical treatment of locally advanced gastric cancer	Andreas Brandl (online)
11:10-11:25	Case report 1: Preoperative ChT-RT of GEJ cancer + discussion	Marina Grbic
11:25-11:40	Case report 2: Metastatic HER2+ gastric cancer + discussion	Vladimir Perduv
11:40-11:55	Case report 3: MSI-H locally advanced gastric cancer + discussion	Jelena Jevtovic
11:55-12:00	Conclusions	
<b>12:15-13:00</b>	<b>Sponsored symposium 2</b> <b>Merck</b> <b>Past, present and future of Merck Oncology</b> Davorin Radosavljevic: Erbitux i Bavencio – past, present and future Marija Ristic, Ivan Nikolic: Erbitux – why two anti-EGFR agents are not the same? Davorin Radosavljevic: Discussion and conclusions Suzana Matkovic: Bavencio in the treatment algorithm of mUC Lazar Popovic: Efficacy and safety of Bavencio in the treatment of mUC – our clinical experience Davorin Radosavljevic: Discussion and conclusions	
<b>13:00-14:20</b>	<b>Scientific symposium 3</b> <b>Multidisciplinary treatment of digestive tract malignancies – part 2:</b> <b>Locally advanced rectal cancer</b> <u>Moderators:</u> Srdjan Nikolic, Davorin Radosavljevic, Suzana Stojanovic Rundic <u>Panelists:</u> Dragan Radovanovic, Biljana Kukic, Marko Dozic, Marija Ristic, Nenad Mijalkovic, Dorin Popa	
13:00-13:15	MRI diagnostics for rectal cancer – current recommendations and treatment decision	Suzana Stojanovic Rundic
13:15-13:30	Surgery of rectal cancer after TNT	Dorin Popa (online)
13:30-13:45	Case report 1: TNT as a consolidation + discussion	Katarina Ljujic
13:45-14:00	Case report 2: Watch & wait strategy + discussion	Mladen Marinkovic
14:00-14:15	Case report 3: Adjuvant chemotherapy + discussion	Jelena Perović



14:15-14:20	Conclusions	
14:20-15:20	LUNCH	
<b>15:20-16:05</b>	<b>Sponsored symposium 3</b> <b>Servier</b> <b>Advancing treatment strategies in GI cancers</b> Moderator: Davorin Radosavljevic Zafir Murtezani: Further Extending the Continuum of Care in mCRC Miljana Dzunic: Novelty in mPDAC treatment guidelines Panel discussion: Zoran Andric, Nebojsa Manojlovic, Nenad Mijalkovic Conclusions	
<b>16:00-17:05</b>	<b>Scientific symposium 4</b> <b>Supportive oncology – digestive symptoms</b> Moderator: Snezana Bosnjak	
16:00-16:10	Chronic nausea and vomiting	Snezana Bosnjak
16:10-16:20	Malignant bowel obstruction	Ana Zilic
16:20-16:30	Constipation in cancer patients	Jelena Dimitrijevic
16:30-16:40	Malnutrition – significance for therapy decision making in oncology	Fedja Djordjevic
16:40-17:00	Q&A, discussion	
17:00-17:05	Conclusions	
17:05-17:10	Break	
<b>17:10-17:40</b>	<b>Sponsored symposium 4</b> <b>Janssen</b> <b>Metastatic hormone-sensitive prostate cancer treatment: discussion on important questions</b>	
<b>17:40-18:00</b>	<b>CLOSING REMARKS &amp; evaluation</b>	